ELIAS JOSEPH JABBOUR to Antibodies, Monoclonal
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Antibodies, Monoclonal.
Connection Strength
0.908
-
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 10 01; 4(10):1413-1420.
Score: 0.266
-
Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015 Jun 25; 125(26):4010-6.
Score: 0.211
-
Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs. 2014 Mar; 19(1):37-50.
Score: 0.191
-
Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666.
Score: 0.058
-
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83.
Score: 0.047
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
Score: 0.042
-
Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009 Apr; 33(4):565-6.
Score: 0.033
-
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.
Score: 0.021
-
Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403.
Score: 0.015
-
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11.
Score: 0.013
-
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92.
Score: 0.010